Key result
In a neonatal murine model of CVA6 infection, prophylactic administration of ribavirin, gamma interferon, and CVA6 vaccines protected mice against homologous challenge and increased survival.
A novel neonatal murine model of CVA6 infection was established, demonstrating protective efficacy of ribavirin, gamma interferon, and vaccines, while showing IL-6 exacerbates the disease.
No takes yet. Share an insight, caveat, or question.
Supports testing of ribavirin, interferon, and vaccines in CVA6 models; leaves open translation to human neonates.
Zhang et al. (2017) studied Coxsackievirus A6 (CVA6) infection. Ribavirin, gamma interferon, and CVA6 vaccines was evaluated on Survival and protection against CVA6-associated pathology. In a neonatal murine model of CVA6 infection, prophylactic administration of ribavirin, gamma interferon, and CVA6 vaccines protected mice against homologous challenge and increased survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: